NKTR Slides as Traders Appear to Sell Positive Trial Update

Nektar Therapeutics (NKTR) is down 19.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied less to a clearly negative headline and more to a sell-the-news reaction after Nektar released updated rezpegaldesleukin data on October 1. The new dataset highlighted durability in alopecia areata and atopic dermatitis, but investors may have been positioned for an even stronger reaction after the stock’s recent momentum, while legal and valuation uncertainty still hang over the name.

Details:

Nektar announced new long-term rezpegaldesleukin data at the EADV Congress on October 1, including maintained alopecia areata responses after treatment stopped and plans to start a Phase 3 alopecia study in early 2027.

The stock had also been supported recently by a September 24 jury verdict awarding Nektar $90 million in damages in its dispute with Eli Lilly, but that outcome remains subject to post-trial proceedings and a possible appeal.

Nektar had entered a quiet period on September 8 ahead of the off-treatment alopecia areata update, so today’s release may have removed a near-term speculative catalyst rather than adding a new surprise.

Sentiment may have already turned more cautious after a September 23 analyst price-target cut to $50 from $80, even though the rating was maintained.

Sources:

Nektar Therapeutics, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NKTR Insider Trading Activity

$NKTR insiders have traded $NKTR stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.

Here’s a breakdown of recent trading of $NKTR stock by insiders over the last 6 months:

HOWARD W ROBIN (President & CEO) has made 0 purchases and 6 sales selling 20,862 shares for an estimated $1,274,229.
JONATHAN ZALEVSKY (Chief R&D Officer) has made 0 purchases and 4 sales selling 11,604 shares for an estimated $760,306.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$NKTR Hedge Fund Activity

We have seen 159 institutional investors add shares of $NKTR stock to their portfolio, and 81 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 2,249,201 shares (+324.7%) to their portfolio in Q2 2026, for an estimated $157,016,721
TWO SEAS CAPITAL LP added 1,133,056 shares (+57.8%) to their portfolio in Q2 2026, for an estimated $79,098,639
FMR LLC added 764,732 shares (+17.8%) to their portfolio in Q2 2026, for an estimated $53,385,940
VESTAL POINT CAPITAL, LP added 715,000 shares (+250.9%) to their portfolio in Q2 2026, for an estimated $49,914,150
GEODE CAPITAL MANAGEMENT, LLC added 534,511 shares (+154.1%) to their portfolio in Q2 2026, for an estimated $37,314,212
INVESCO LTD. removed 487,602 shares (-85.9%) from their portfolio in Q2 2026, for an estimated $34,039,495
BRAIDWELL LP added 473,617 shares (+inf%) to their portfolio in Q2 2026, for an estimated $33,063,202

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NKTR Price Targets

Multiple analysts have issued price targets for $NKTR recently. We have seen 5 analysts offer price targets for $NKTR in the last 6 months, with a median target of $178.0.

Here are some recent targets:

Martin Fan from Wedbush set a target price of $80.0 on 05/11/2026
Yasmeen Rahimi from Piper Sandler set a target price of $192.0 on 05/08/2026
Samantha Semenkow from Citigroup set a target price of $151.0 on 04/21/2026
Arthur He from HC Wainwright & Co. set a target price of $185.0 on 04/20/2026
Julian Harrison from BTIG set a target price of $178.0 on 04/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.